Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 27Cyclophosphamide 14Gemcitabine 13fludarabine 11Carboplatin 10aldesleukin 9Trastuzumab 9Specimen Handling 9Nivolumab 9Magnetic Resonance Spectroscopy 8Biopsy 8olaparib 7Cisplatin 7Paclitaxel 6palbociclib 5atezolizumab 5Taxes 5Early Intervention, Educational 5Oxaliplatin 4Methods 4Irinotecan 4Drug Therapy 4Docetaxel 4Cetuximab 4Capecitabine 4Bevacizumab 4Albumin-Bound Paclitaxel 4talazoparib 3spartalizumab 3pertuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × amivantamab × Gynecologic × Clear all
NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡